Katarina Fröschle

Associate

Hamburg
katarina.froeschle@lw.com
+49.40.4140.3154

PRACTICES

  • Mergers & Acquisitions
  • Private Equity

INDUSTRIES

  • Healthcare & Life Sciences

BAR QUALIFICATIONS

  • Rechtsanwältin (Germany)

EDUCATION

  • Second German State Exam, Higher Regional Court, Hamburg,
  • First German State Exam, Bucerius Law School,

LANGUAGES SPOKEN

  • German
  • English
  • Croatian
  • French

PROFILE

Katarina Fröschle is an associate in the Hamburg office of Latham & Watkins and practices in the firm’s Corporate Department.

She advises German and international clients primarily in the areas of mergers and acquisitions, private equity, and general corporate law.

Katarina studied law at the Bucerius Law School in Hamburg and at the Université de Paris 1-Panthéon-Sorbonne in Paris. During her legal clerkship, she gained experience in the Corporate Department of the Hamburg office of Latham & Watkins and in the M&A department of HELIOS Kliniken GmbH, Berlin.

Before joining Latham & Watkins, Katarina also worked as a research assistant to Professor Holger Fleischer at the Max Planck Institute for International and Foreign Private Law in Hamburg.

EXPERIENCE

Katarina’s experience includes advising:

  • Astellas Pharma on the sale of a pharmaceutical portfolio 
  • Novo Holdings AS on the €25 million extended Series C financing for AMSilk 
  • Trade Republic on its US$900 million Series C financing
  • One Rock on the acquisition of Constantia Flexibles
  • Froneri on the sale of its frozen food business Findus 
  • IK Partners on its investment in Cinerius Financial Partners
  • Cheplapharm on the acquisitions of:
    • The worldwide commercial rights for Zyprexa®, the olanzapine/olanzapine pamoate monohydrate portfolio for the treatment of schizophrenia and bipolar disorders, from Eli Lily and Company 
    • The US Marketing Authorization for Pulmicort Flexhaler, a Budesonide inhalation powder for the treatment of Asthma, from AstraZeneca AB
    • A further product portfolio
    • The medicinal product Atacand from AstraZeneca 
  • Triton on the sale of COBEX 
  • Triton and Abu Dhabi Investment Authority (ADIA) on the Acquisition of IFCO
  • Charité University Hospital and German Heart Center on the formation of University Heart Center Berlin
  • Consortium of shareholders, including funds advised by H.I.G. Capital, other private equity investors and management, on the sale of DSD - Duales System Holding GmbH & Co. KG to Remondis SE & Co. KG
  • Confidential client in connection with buy-and-build projects in German outpatient care sectors
  • The Carlyle Group on the intended acquisition of the assets divested in connection with the Linde Praxair merger
  • The Carlyle Group in connection with the divestiture of Klenk Holz AG
  • Capvis Equity Partners on the acquisition of a majority stake in the Amann Girrbach Group, one of the world’s leading companies in the field of digital dental technology
  • Astellas Pharma on an ongoing transaction
  • Daimler AG on the investment in Toll Collect
  • Ergon Capital Partners on the acquisition of svt Holding GmbH, an expert in fire protection and damage remediation
  • Unternehmensinvest AG on the acquisition of a majority stake in the Kautex Maschinenbau Group, one of the world’s leading suppliers of extrusion blow molding technology